Reem Karmali

4.2k total citations
116 papers, 1.0k citations indexed

About

Reem Karmali is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Reem Karmali has authored 116 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pathology and Forensic Medicine, 53 papers in Oncology and 41 papers in Genetics. Recurrent topics in Reem Karmali's work include Lymphoma Diagnosis and Treatment (75 papers), Chronic Lymphocytic Leukemia Research (38 papers) and CAR-T cell therapy research (20 papers). Reem Karmali is often cited by papers focused on Lymphoma Diagnosis and Treatment (75 papers), Chronic Lymphocytic Leukemia Research (38 papers) and CAR-T cell therapy research (20 papers). Reem Karmali collaborates with scholars based in United States, Philippines and Switzerland. Reem Karmali's co-authors include Leo I. Gordon, Parameswaran Venugopal, Andrew M. Evens, Jane N. Winter, Sonali M. Smith, Barbara Pro, Irene Helenowski, Jeffrey A. Borgia, Scott E. Smith and Chadi Nabhan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Reem Karmali

97 papers receiving 1.0k citations

Peers

Reem Karmali

PFM

ONCOL

NEURO

GENET

IMMUN

Allison Crosby‐Thompson United States

Woo‐Ick Yang South Korea

Evert-Jan G. Boerma Netherlands

Cathrin Skrabs Austria

Igor Aurer Croatia

Alice Di Rocco Italy

Niels Murawski Germany

Viola Poeschel Germany

Geoffrey Chong Australia

Marc André France

Allison Crosby‐Thompson United States

Reem Karmali

675 ×1.0

PFM

393 ×0.7

ONCOL

239 ×1.0

NEURO

181 ×0.9

GENET

146 ×0.9

IMMUN

Citations per year, relative to Reem Karmali Reem Karmali (= 1×) peers Allison Crosby‐Thompson

Countries citing papers authored by Reem Karmali

Since Specialization

Citations

This map shows the geographic impact of Reem Karmali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reem Karmali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reem Karmali more than expected).

Fields of papers citing papers by Reem Karmali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reem Karmali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reem Karmali. The network helps show where Reem Karmali may publish in the future.

Co-authorship network of co-authors of Reem Karmali

This figure shows the co-authorship network connecting the top 25 collaborators of Reem Karmali. A scholar is included among the top collaborators of Reem Karmali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reem Karmali. Reem Karmali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Torka, Pallawi, Natalie S. Grover, Timothy Voorhees, et al.. (2025). Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study. Hematological Oncology. 43(3). e70087–e70087. 1 indexed citations

Epperla, Narendranath, Geoffrey Shouse, Jess Hatfield, et al.. (2025). Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study. Blood. 146(Supplement 1). 4534–4534.

Maris, Michael B., Gilles Salles, Won Seog Kim, et al.. (2024). ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. Targeted Oncology. 19(3). 321–332. 4 indexed citations

Dinner, Shira, et al.. (2024). Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity. Journal of Oncology Pharmacy Practice. 30(5). 945–949. 1 indexed citations

Tun, Aung M., Romil Patel, Alex Niu, et al.. (2024). Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study. American Journal of Hematology. 99(9). 1712–1720. 4 indexed citations

Lin, Adam Yuh, Jonathan Moreira, Kenneth R. Carson, et al.. (2024). CT-630 No Impact of Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S611–S612.

Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.

Epperla, Narendranath, Geoffrey Shouse, Natalie S. Grover, et al.. (2023). Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. Blood. 142(Supplement 1). 5147–5147.

Karmali, Reem, Jeremy S. Abramson, Deborah M. Stephens, et al.. (2023). Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Advances. 7(23). 7361–7368. 3 indexed citations

10.

Dalal, Prarthana, Abigail S. Baldridge, Arjun Sinha, et al.. (2023). Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T‐cell therapy. European Journal Of Haematology. 112(1). 102–110. 10 indexed citations

11.

Ruan, Jia, Jasmine M. Zain, Borko Jovanovic, et al.. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances. 7(19). 5771–5779. 19 indexed citations

12.

Trabolsi, Asaad, Narendranath Epperla, Lindsey Fitzgerald, et al.. (2023). A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma. Blood. 142(Supplement 1). 3770–3770. 1 indexed citations

13.

Hill, Brian T., Shuo Ma, Clive S. Zent, et al.. (2023). Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia. Blood Advances. 8(2). 378–387. 4 indexed citations

14.

Grover, Natalie S., Pallawi Torka, Marcus P. Watkins, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances. 7(22). 6839–6843. 3 indexed citations

15.

Rink, Jonathan S., Adam Yuh Lin, Kaylin M. McMahon, et al.. (2020). Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. Journal of Biological Chemistry. 296. 100100–100100. 42 indexed citations

16.

Diefenbach, Catherine, Fangxin Hong, Richard F. Ambinder, et al.. (2020). Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. The Lancet Haematology. 7(9). e660–e670. 97 indexed citations

17.

Epperla, Narendranath, Namrata Shah, George Carrum, et al.. (2017). Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 17(7). 408–414. 8 indexed citations

18.

Karmali, Reem, Eva Kimby, Michele Ghielmini, et al.. (2017). Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Annals of Oncology. 29(2). 332–340. 13 indexed citations

19.

Straus, David C., et al.. (2013). Impact of therapeutic regimen and clinical presentation on overall survival in CNS lymphoma. Acta Neurochirurgica. 156(2). 355–365. 8 indexed citations

20.

Evens, Andrew M., Irene Helenowski, Chadi Nabhan, et al.. (2011). Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. Blood. 118(21). 2625–2625.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact